Apel­lis ris­es on long-term da­ta for Soliris chal­lenger af­ter mixed PhI­II read­out, and an­a­lysts are more bull­ish on ap­proval

Apel­lis Phar­ma­ceu­ti­cals took a beat­ing last Sep­tem­ber af­ter da­ta from two Phase III stud­ies showed con­flict­ing da­ta over whether its eye dis­ease drug worked in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER